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http://www.springerplus.com/content/2/1/366RESEARCH Open AccessIs Age-targeted full-field digital mammography
screening cost-effective in emerging countries?
A micro simulation model
Fabiano Hahn Souza1,2,3* and Carísi Anne Polanczyk1,2Abstract
Objective: The present paper estimates the cost-effectiveness of population-based breast cancer (BC) screening
strategies in Brazil for women under 50 years from the perspective of the Brazilian public health system.
Methods: A Markov model, simulating the natural history of female BC sufferers in Brazil, was developed. This
model compares the lifetime effects, costs, and cost-effectiveness of seven BC screening strategies in women
between 40 to 49 years: (A) usual care; (B) annual screen-film mammography (SFM); (C) SFM every 2 years; (D)
annual full-field digital mammography (FFDM); (E) FFDM every 2 years; and (F and G) age-targeted options, with
FFDM annually until 49 years and SFM annually (or biannually) from 50 to 69 years.
Results: Adopting SFM every 2 years (Strategy C) was found to be slightly more costly but also more effective in
terms of quality-adjusted life years (QALYs), yielding an incremental cost-effectiveness ratio (ICER) of R$ 1,509 per
QALY gained. Annual SFM (Strategy B) was the next best option at an additional R$ 13,131 per QALY gained. FFDM
annual screening (Strategy E) was dominated by Strategy F, the age-targeted option. For younger women, the
age-based strategy had an ICER of R$ 30,520 per QALY gained. In the sensitivity analysis, the ICERs ranged from R$
15,300 to R$ 257,899 in different regions of the country, depending on BC incidence, population age distribution,
and mammography coverage.
Conclusions: SFM every 2 years for all women starting between the ages of 40 and 49 would be a cost-effective
strategy. Taking into account regional specificities, age-targeted FFDM is one option to improve the outcomes of
BC patients in an emerging country.Introduction
Breast cancer (BC) is the most frequently diagnosed can-
cer and the leading cause of cancer among females,
accounting for 23% of total cancer diagnoses and 14% of
overall cancer deaths (Jemal A et al. 2011). Moreover,
BC is now the leading cause of cancer-related death
among females in developing countries, a shift from the
previous decade when cervical cancer was the most
common cause of cancer-related death. Although cancer
incidences and patterns differ according to level of hu-
man development, female BC is the only type of cancer
that is common in all regions of the world. Thus, the* Correspondence: hahnfabiano@hotmail.com
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reproduction in any medium, provided the origglobal control of BC through both early detection and
primary prevention is a high priority (Bray et al. 2012).
Specifically in the context of this study, there is a high
incidence of BC in the female population in Brazil with
more than 50 new cases diagnosed per 100,000 women
every year (INCA 2008).
Major advances in the early diagnosis of some cancers
and a better understanding of the pathogenesis of the
disease have led to risk reduction and prevention strat-
egies. These advances as well as improvements in therapy
have all contributed to declines in cancer-related death
rates (Jemal et al. 2008). However, these successes have
come with substantial increases in cost, causing a serious
financial burden on patients, families, and society at large
(Meropol et al. 2009). Currently, the most effective method
for preventing premature mortality and morbidity due to
BC is the increased use of screening programs and adjuvant. This is an Open Access article distributed under the terms of the Creative
mmons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
inal work is properly cited.
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detection strategies are preferred to adjuvant therapies
because they result in less morbidity.
For the past 30 years, conventional screen-film mammog-
raphy (SFM) has been the method of choice for the radio-
logical evaluation of the breast (Tabar & Dean 2008). The
demonstration of the efficacy of mammography in reducing
BC mortality by approximately 15% in younger women
(<50 years) (Nelson et al. 2009) led to recommendations in
some countries to introduce routine screening programs
for this subgroup (Schopper & de Wolf 2009). However,
considerable controversy over whether screening is effective
for women aged 40–49 years has halted the adoption of
a broad screening approach. Further, because SFM has
lower sensitivity mainly due to the greater breast density
and higher rates of tumor growth in younger women
(Buist et al. 2004), full-field digital mammography (FFDM)
has been shown to be superior to SFM in this subgroup
(Souza et al. 2013; Pisano et al. 2008; Skaane et al. 2007).
FFDM is based on a different technology, in which each
exposure produces a digital image (Tice & Feldman
2008). Although BC age-targeted screening (digital for
women <50 years) is reasonably cost-effective in the US
(Tosteson et al. 2008), no studies of the cost-effectiveness of
FFDM screening in younger women have yet been carried
out in middle-income countries. The objective of this study
is thus to explore the cost-effectiveness of population-based
BC screening using different strategies for women aged
40–49 years in the Brazilian public health system.
Material and methods
Mathematical model
The developed mathematical model was constructed using
decision analysis software (TreeAgePro2009 Suite, release
1.0.2, Tree Age Software, Inc., Williamstown, MA). Specif-
ically, a Markov model was used to compare populations
of young women in Brazil. The structure of the model
(Figure 1) is similar to other models used for BC screening
programs and characterizes the complexity of the natural
history of the disease (e.g., invasive stages are defined
following the tumor–node–metastasis classification
(Edge et al. 2010; van Oortmarssen et al. 1990; Szeto &
Devlin 1996; Rojnik et al. 2008).
In the real world, women diagnosed with BC have
a relatively high risk of developing a new cancer or a
recurrent disease. Women who develop a recurrent
disease will create extra cost and utilities for the state
in line with the basal risk of recurrence of the higher
Markov state.
The micro simulation approach with a cycle length of
1 year with half-cycle correction was chosen for this
study. BC incidence, mammography sensitivity, mortality,
and relative survival rate were modeled as time-dependent
transition probabilities.We considered the following seven BC screening
strategies for women aged 40–49 years: (A) usual care;
(B) annual SFM; (C) SFM every 2 years; (D) annual
FFDM; (E) FFDM every 2 years; (F) “age-targeted digital”
(i.e., annual FFDM for the 40–49 age group and annual
SFM for the 50–69 age group); and (G) “age-targeted
digital” (annual FFDM for the 40–49 age group and SFM
every 2 years for the 50–69 age group). These strategies
were based on the findings of previous studies (Schopper &
de Wolf 2009; US Preventive Services Task Force 2009) and
they included the current status of the Brazilian public
health system (Strategy A “no formal BC screening” as
the base case). According to DATASUS, the Brazilian
public health system database, the annual utilization of
SFM is approximately 17.5% in women above 50 years
(Ministério_Saúde_Brasil, DATASUS 2011).
To determine whether the increased costs of screening
strategies are warranted by health gains compared with
usual care, we assessed the cost-effectiveness of these seven
screening strategies from a public healthcare perspective.
The time horizon covered the full lifetimes of the sample
population from age 40 onward. Mammography screening
stops after 69 years as recommended by the Brazilian
National Cancer Institute (INCA) (INCA 2007). The
starting age for the micro simulation ranged from 40
to 49 years based on the Brazilian population census
(IBGE 2010).
Model calibration
Data on age-dependent cancer incidence were obtained
from the Population-based Cancer Registry in Brazil
(INCA 2010). The clinical-stage distributions for usual
care and screening strategies were used from INCA
(INCA 2011) and from the literature, respectively. Table 1
presents the main parameters used in the model.
Transitions to Markov states are governed by the rate
of incidence, clinical-stage distribution data, and sojourn
time. We modeled for an increase in the incidences of in
situ carcinomas through the introduction of screening
mammography (Kerlikowske 2010). Ten years after the
introduction of these screening programs, ductal car-
cinoma in situ (DCIS) incidence rates were assumed to
have stabilized.
Moreover, evidence of better prognostic screening
compared with the pre-screening era for in situ cancer
cases was incorporated into our model (Ernster et al. 2000),
while over diagnosis was adjusted for confounding and lead
time bias according to the findings of Smith and Duffy
(Smith & Duffy 2011). The risks and benefits of screen-
ing schedules were also adapted from Mandelblatt et al.
(Mandelblatt et al. 2009). BC prognosis subgroups were
then determined for advanced disease status: Luminal
A, Luminal B, HER2-enriched, and triple negative
(Kennecke et al. 2010). Screened BC has been shown
Figure 1 The disease process model for breast cancer.
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with non-screened BC (Mook et al. 2011). Finally, we also
adjusted BC recurrence risk based on BC subgroup, expos-
ure to adjuvant/palliative chemotherapy, adjuvant/palliative
trastuzumab, and adjuvant/palliative endocrine therapy
based on previous findings (Perez et al. 2011; Hortobagyi
1998; Mauri et al. 2006; Mouridsen et al. 2003; Mouridsen
et al. 2001; Slamon et al. 2001).
Patterns of stage-specific treatments were adapted
from DATASUS and from the literature. For DCIS, two
treatments were possible: surgery with or without radio-
therapy (Wapnir et al. 2011; Baxter et al. 2004; Meijnen
et al. 2008). For invasive BC, five treatments were possible:
surgery, anti-HER2 adjuvant biologic therapy, radio-
therapy, chemotherapy, and endocrine therapy. The
last three treatments could be used in an adjuvant as
well as in a palliative setting, while anti-HER2 therapy
was only allowed in adjuvant stage 2 and 3 settings forHER2-positive patients for 1 year (Perez et al. 2011).
Further, the sensitivity of the mammography in the
base case was adapted from Breast Cancer Surveillance
Consortium (BCSC) data (Kerlikowske et al. 2011). The
BCSC database was chosen because it is the largest source
of effectiveness data from population screening using both
film and digital technology.
The deployment of an FFDM screening program may
cause higher recall rates compared with an SFM-based
program (Bluekens et al. 2010). For the first round of
screening in the present study (prevalence screening),
recall rates were 4.29% and 3.41% for FFDM and SFM,
respectively. For the second round (incidence screening), re-
call rates were 1.69% and 1.01% (Bluekens et al. 2010). We
assumed that all recalled women would undergo another
mammography and/or ultrasound. Approximately 5% and
3% of the recalled women underwent fine needle aspiration
and surgical biopsy, respectively (Moss et al. 2006).
Table 1 Main parameters used in the base case and sensitivity analyses
Variables Screening test performance Distribution/comments Reference
Mean Minimum Maximum
Mammography coverage 18% 10% 30% Uniform (Ministério_Saúde_Brasil, DATASUS 2011)
Mammography coverage ǁ 70% 55% 85% Uniform (Lilliu et al. 2002)
Sensitivity of SFM (40–49 years) 76% 60% 85% Effectiveness data from large population (Kerlikowske et al. 2011)
Sensitivity of FFDM (40–49 years) 82% 65% 90% Effectiveness data from large population (Kerlikowske et al. 2011)
Sensitivity of SFM (50–59 years) 85% 65% 90% Effectiveness data from large population (Kerlikowske et al. 2011)
Sensitivity of FFDM (50–59 years) 80% 65% 90% Effectiveness data from large population (Kerlikowske et al. 2011)
Sensitivity of SFM (60–69 years) 83% 65% 90% Effectiveness data from large population (Kerlikowske et al. 2011)
Sensitivity of FFDM (60–69 years) 90% 65% 95% Effectiveness data from large population (Kerlikowske et al. 2011)
Treatment complication (yearly) - Chemotherapy 16% 10% 20% Resource utilization database (Hassett et al. 2006)
Treatment complication (yearly) – Endocrine therapy 5% 1% 10% Resource utilization database (Hassett et al. 2006)
Overdiagnosis 5% 0 30% Systematic review estimate (Smith & Duffy 2011)
Cancer stage distribution
Mean CI* 95%
DCIS (clinical diagnostic) 6.1% 4.9–7.3% Beta (α = 97; β = 1494) (INCA 2009b; Martins et al. 2009)
State 1 (clinical diagnostic) 14% 13.1–16.6% Beta (α = 232; β = 1329) (INCA 2009b; Martins et al. 2009)
State 2 (clinical diagnostic) 38.6% 36.5–40.5% Beta (α = 915; β = 1455) (INCA 2009b; Martins et al. 2009)
State 3 (clinical diagnostic) 34.7% 32.4–37.1% Beta (α = 546; β = 1028) (INCA 2009b; Martins et al. 2009)
State 4 (clinical diagnostic) 10.8% NA Complementary (INCA 2009b; Martins et al. 2009)
CDIS (screening diagnostic) 6.1% NA Dynamic range ∫ (Kerlikowske et al. 2011)
State 1 (screening diagnostic) 58%Ξ NA Effectiveness data from large population (Kerlikowske et al. 2011)
State 2 (screening diagnostic) 32.4%Ξ NA Effectiveness data from large population (Kerlikowske et al. 2011)
State 3 (screening diagnostic) 8.3%Ξ NA Effectiveness data from large population (Kerlikowske et al. 2011)
State 4 (screening diagnostic) 1.3%Ξ NA Effectiveness data from large population (Kerlikowske et al. 2011)
Transition probabilities
BC Recurrence Mean Range Local Regional/systemic
CDIS 0.008/y 0.002–0.014/y 50–98% 2–50% (Baxter et al. 2004; Meijnen et al. 2008)
Stage 1 0.030/y NA 16–47% 53–84% (Hirsch et al. 2011a; Hirsch et al. 2011b)
Stage 2 0.087/y NA 19–56% 44–81% (Wapnir et al. 2006)
Stage 3 0.283/y 0,11–0,28/y 19–56% 19–56% (Wapnir et al. 2006)
BC Death Mean Range
CDIS 0.002/y 0.002–0.003/y (Ernster et al. 2000)
Stage 1 0.009/y NA (de Oliveira et al. 2009)















Table 1 Main parameters used in the base case and sensitivity analyses (Continued)
Stage 3 0.090/y NA (de Oliveira et al. 2009)
Stage 4 0.270/y 0.20–0.34 (de Oliveira et al. 2009)
Relative risk Distribution/comments
Mean
Adjuvant Taxane chemotherapy§ 0.86 Log-Normal (μ = −0.15;σ=0.07) (Peto et al. 2012)
Adjuvant Aromatase inhibitor§¶ 0.82 Log-Normal (μ = −0.20;σ=0.12) (Dowsett et al. 2010)
Adjuvant Trastuzumab therapy §‡ 0.61 Log-Normal (μ = −0.49;σ=0.06) (Perez et al. 2011)
Screening vs. non-screening cancer casesΦ 0,62 Log-Normal (μ= − 0.48;σ=0.12) (Mook et al. 2011)
Advanced disease - Luminal A vs. Luminal B¥ 1.42 Log-Normal (μ = 0.34;σ=0.12) (Kennecke et al. 2010)
Advanced disease - Luminal A vs. HER2 + ¥ 1.90 Log-Normal (μ=0.64;σ=0.11) (Kennecke et al. 2010)
Advanced disease - Luminal A vs. Triple negative¥ 1.62 Log-Normal (μ = 0.48;σ=0.11) (Kennecke et al. 2010)
Relative odds ratio Distribution/comments
Mean
Diagnostic cancer downstage (FFDM under 50 years) 0.54 Log-Normal (μ= − 0.654;σ=0.307) (Souza et al. 2013)
Mean Minimum Maximum
Discount rate 5% 0% 10% Brazilian Health Economic Guidelines (Ministério_Saúde_Brasil 2009)
Costs (Brazilian Real)
Mean Minimum Maximum
Medical visit 10 5 25 DATASUS (Ministério_Saúde_Brasil, DATASUS 2011)
FFDM 68 45 90 Estimated∀ (Souza 2012)
SFM 45 30 60 DATASUS (Ministério_Saúde_Brasil, DATASUS 2011)
Biopsy 429 150 700 Gamma (α = 14.93; λ = 0.03) (Souza 2012)
Recall SFM 152 50 250 Aggregate costs (Souza 2012)
Recall FFDM 197 100 300 Aggregate costs (Souza 2012)
Staging early BCΨ 509 250 750 Gamma (α = 3.09 λ=0.01) (Souza 2012)
Staging locally and advanced cancerΔ 592 200 800 Gamma (α = 2.52 λ=0.04) (Souza 2012)
Invasive cancer stage 1 (first year) 6,502 2,500 11,500 Aggregate costs (Souza 2012)
Invasive cancer stage 2 (first year) 15,610 6,500 24,500 Aggregate costs (Souza 2012)
Invasive cancer stage 3 (first year) 18,638 9,500 27,500 Aggregate costs (Souza 2012)
Invasive cancer stage 4 (first year) 12,452 6,500 20,500 Aggregate costs (Souza 2012)
Invasive cancer stage 1 (≥ 2 year) 602 200 1,000 Aggregate costs (Souza 2012)
Invasive cancer stage 2 (≥ 2 year) 677 200 1,200 Aggregate costs (Souza 2012)
Invasive cancer stage 3 (≥ 2 year) 742 200 1,600 Aggregate costs (Souza 2012)















Table 1 Main parameters used in the base case and sensitivity analyses (Continued)
Utilities
Mean CI* 95%
Healthy woman 0.800 NA South of Brazil population⊥ (Cruz 2010)
Healthy woman – false positive mammography 0.795 NA Estimated∴ (Cruz 2010)
Non metastatic BCχ – follow-up 0.772 0.63–0.90 Normal distribution (Souza 2012; Cruz 2010)
Early BCχ – Adjuvant Endocrine Therapy 0.762 0.62–0.91 Normal distribution (Souza 2012; Cruz 2010)
Early BCχ – Adjuvant Chemotherapy 0.739 0.61–0.87 Normal distribution (Cruz 2012; Cruz 2010)
Clinical Stage 3 – Adjuvant Endocrine Therapy 0.760 0.59–0.95 Normal distribution (Souza 2012; Cruz 2010)
Clinical Stage 3 – Adjuvant Chemotherapy 0.700 0.63–0.78 Normal distribution (Souza 2012; Cruz 2010)
Clinical Stage 4 – Advanced disease 0.680 0.57–0.80 Normal distribution (Souza 2012; Cruz 2010)
ǁ Screening strategies; NA: not applicable; ∫ time and screening coverage-dependent (increase in the DCIS rate with the introduction of the screening program); Ξ relative to invasive cancer (excluding DCIS); § Relative
risk of BC death in clinical stage 2 and 3 patients; ¶ hormone-positive patients; ‡ HER2-positive patients; Φ Relative risk of BC death; ¥ Relative risk of BC death in advanced disease (stage 4) according to prognostic
subtype; ∀ Plausible estimate 50% above SFM reimbursement value; Ψ clinical stages 1 and 2; Δ clinical stages 3 and 4; * confidence interval; ⊥ Porto Alegre city; ∴Considering the mean of non-metastatic BC utility
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of Geography and Statistics Census (2010) and BC deaths
were calibrated based on the Mortality Information System
of Brazil (DATASUS 2000).
We tested whether the model was calibrated according
to the life expectancy of Brazilian women (IBGE 2010).
The model does not include input parameters for life
expectancy, which is estimated indirectly as a function
of the parameters for relapse rates, progression, and
overall and BC deaths. Thus, the life expectancy of Brazilian
women was defined as an appropriate parameter to validate
the model in Brazil. Figure 2 presents the life expectancy
predicted in the model at a 95% confidence interval.
Screening and participation rates
There is no formal screening activity in Brazil (despite some
isolated initiatives at a regional level). Therefore, opportun-
istic screening is considered to be usual care in the Brazilian
public health system. DATASUS shows that approxi-
mately 18% of women above 50 have undergone SFM
(Ministério_Saúde_Brasil, DATASUS 2011). A Brazilian
prospective cohort achieved a similar opportunistic screen-
ing rate of approximately 24% (Marchi & Gurgel 2010).
Finally, annual participation rates ranged from 18% to 70%.
Costs and health outcomes
Table 1 presents the costs and utilities applied in the model.
Total costs consist of the costs of primary care consultancy,
mammography screening, additional work-up exams
(when required), cancer diagnostic procedures (images,
biopsy, pathology), cancer staging (images), cancer treat-
ment (surgery, radiotherapy, chemotherapy, anti-HER2,
and endocrine therapy), and cancer follow-up. Costs
were obtained from Ministério_Saúde_Brasil, DATASUSFigure 2 Model predicted life expectancy and 95% confidence interva
Institute of Geography and Statistics Cencus.(2011) and the BC database of resource utilization in the
public healthcare system in Brazil (Souza 2012). All costs
are expressed in 2010 Brazilian Real (US$ 1 = R$ 1.67).
Quality-adjusted life years (QALYs) were estimated based
on the patient’s SF-6D scores (Souza 2012; Cruz 2010).
Base case analysis
Using a set of natural history input parameters, we calcu-
lated the expected costs and effectiveness of each strategy
in base case and sensitivity analyses. The costs and effects
of each simulated screening program were then assessed.
Future costs and health effects (e.g., life years and utilities
losses) were discounted at a rate of 5% according to the
Brazilian Guidelines for Health Technology Assessment
(Ministério_Saúde_Brasil 2009). After ranking them in
order of increasing costs and eliminating all dominant
strategies (greater cost and fewer benefits than any other
combination of strategies), we calculated incremental cost-
effectiveness ratios (ICERs).
Since there is no recommended threshold to deter-
mine whether an intervention is cost-effective in Brazil
(Ministério_Saúde_Brasil 2009), we adapted the recommen-
dations of the World Health Organization, which suggests
that a cost-effective intervention would avert one additional
disability-adjusted life year for less than three times average
per capita GDP (World Health Organization 2001). We
assumed that society’s willingness to pay (WTP) for one
additional disability-adjusted life year was equivalent to
its WTP for one QALY. This approach has been used in
previous economic evaluations performed in Brazil and
in other middle-income countries (Goldie et al. 2007;
Goldie et al. 2008; Vanni et al. 2010; Vanni et al. 2012).
Programs that were more costly and less effective than
other programs were immediately ruled out as inefficientl for women 40 years and older, and estimates from the Brazilian
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remaining programs constituted the frontier of efficient
screening programs.
Sensitivity analysis
To assess uncertainty in the model, one-way, scenario,
and probabilistic sensitivity analyses were conducted. In
one-way sensitivity analysis, the key parameters were
varied using minimum and maximum values, as shown
in Table 1. A probabilistic sensitivity analysis was also
performed to explore joint uncertainty across parameters.
By sampling the distribution of the model parameters,
we generated 10,000 estimates for the costs and effects
of each strategy. These estimates were plotted on a cost-
effectiveness plane and cost-effectiveness acceptability
curves were used to depict the level of uncertainty for
the optimal strategy at different WTP thresholds for an
additional QALY (Barton et al. 2008).
Results
Base case analysis
In the base case analysis, with a simulated cohort starting
at 40 years, we found that the mean survival period
(adjusted for quality) for usual care was 14,498, at a
lifetime cost of R$ 2,075. All other screening strategies were
associated with higher QALYs and additional costs. Table 2
presents the ICER results for the base case analysis. The
discounted QALYs for the seven strategies were similar
to those found in previous BC screening studies, while
the differences between these strategies were small
(Tosteson et al. 2008; Rojnik et al. 2008). However, there
were greater differences in terms of expected lifetime costs.
Thus, the costs and effectiveness of the strategies were
considered to identify which strategy represented better
value for money. Figure 3 and Table 2 show that usual care
(Strategy A) was the cheapest but least effective strategy.
Adopting SFM every 2 years (Strategy C) was slightly
more costly but also more effective, yielding an ICER
of R$ 1,509 per QALY gained. The next best alternative
also adopted SFM, but now annually (Strategy B), which
was cost-effective at an additional R$ 13,131 per QALYTable 2 Base-case incremental cost effectiveness results
Strategy Discounted costs
(Brazilian Real)
Strategy A - Usual care 2,075
Strategy B - SFM annual 2,318
Strategy C – SFM every 2 years 2,125
Strategy D – FFDM annual 2,564
Strategy E – FFDM every 2 years 2,259
Strategy F – FFDM (<50) and SFM (50–69) annual 2,393
Strategy F – FFDM annual (<50) and SFM
(50–69) every 2 years
2,254gained. FFDM annual screening (Strategy E) was dominated
by Strategy F, which is an age-targeted option, with FFDM
used annually until 49 years and SFM annually from 50 to
69 years. For younger women (<50 years), this is the most
effective strategy. With an ICER of R$ 30,520, Strategy
F could also be considered to be a cost-effective strategy
for an emerging country such as Brazil.
Sensitivity analysis
In the one-way sensitivity analysis, the ranking of the seven
strategies remained unchanged for most model parameters.
The results were most sensitive to changes in the coverage
of opportunistic screening under usual care (Strategy A). At
a coverage rate of approximately 30%, SFM every 2 years
showed cost savings. Although the discount rate and BC
incidence seemed to play an important role in determining
the magnitude of ICERs, they did not change the order of
the strategies that composed the cost-effectiveness frontier.
Figure 4 presents the range of ICERs according to BC
incidence, age distribution, and mammography coverage
by Brazilian region (INCA 2010; MS 2011). In regions that
have a lower BC incidence (e.g., Belem and Cuiaba city),
ICERs have a higher probability of not being cost-effective
(R$ 257,889 and R$ 49,362, respectively). On the contrary,
for regions that have a higher BC incidence (e.g., São Paulo
and Recife), the ICER is approximately R$ 21,000. The best
scenario was in Porto Alegre, with an ICER of R$ 15,300.
Figure 5 reports the results of the probabilistic sensitivity
analysis. By adopting the threshold suggested by the
Commission for Macroeconomics in Health for cost-
effectiveness interventions (R$ 17,869/QALY), and by
considering both SFM strategies (annual and every 2 years),
we found a high probability that SFM is a cost-effective
approach for the Brazilian public health system (approxi-
mately 70% of the simulations). Moreover, at a much lower
ICER of R$ 6,000/QALY, SFM every 2 years was cost-
effective in more than 95% of the simulations.
Nonetheless, it is important to recognize that FFDM is
increasingly used by institutions in Brazil. When we con-
sider a cost-effective threshold of three times national












Figure 3 Cost Effectiveness plane (base-case).
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cost-effective (approximately 60% of the simulations).
Considering a WTP of R$ 20,000/QALY, 10% of the
simulations with Strategy F would be considered to be
cost-effective. In the case of a WTP of R$ 100,000/QALY,
this figure grew to 70% of the simulations.Figure 4 Sensitivity analysis. Shown is the range of the incremental cost
assumptions for screening strategy (breast cancer incidence, populational aDiscussion
BC incidence varies considerably throughout the world;
indeed, age-standardized incidence is approximately
fourfold higher in high-income countries in North America
and Western Europe compared with countries that
have a lower per capita income (Legorreta et al. 1996).-effectiveness ratios (ICERs) as a result of varying parameters and
ge distribution and mammography coverage).
Figure 5 Cost Effectiveness acceptability curve (dominated strategies not shown).
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incidence of BC and average GDP per capita has been
demonstrated (Lilliu et al. 2002). However, in many
low- and middle-income countries, incidence is increasing
faster than that in developed nations, where incidence is
already high (Cody 1996).
In many Western countries, mammography screening
has become the standard of care for the early detection of
BC. Despite its widespread use, however, mammography
is a far from a perfect means of early detection. Several
limitations have been recognized, such as in the areas
of false positive results, ethnic and biological differences,
social and cultural barriers, and the harm-to-benefit
ratio (Lu et al. 2012). Some studies have demonstrated
that SFM can be cost-effective in Western countries
(<US$ 50,000/QALY) (Tosteson et al. 2008; Szeto &
Devlin 1996; Lindfors & Rosenquist 1995), whereas
its benefit is more questionable in low- and middle-
income countries (Rojnik et al. 2008; Okonkwo et al.
2008; Jakubowski et al. 1996).
Our Markov model shows that using SFM to screen
for BC is a cost-effective strategy for the public health
system in Brazil, a middle-income country. Considering
the cost-effective threshold given by Brazil’s GDP per
capita, SFM every 2 years is the strategy that has the best
cost-effectiveness profile (ICER below the threshold and
high probability of being cost-effective in the probabilistic
sensitivity analysis). Gains in QALYs are likely to occur
due to the earlier diagnostic stage of BC in women, which
compensates for the additional cost of mammography
screening, medical consultations, false positive results, the
increase in the incidence of DCIS after the screening pro-
gram has been deployed, and the over diagnosis of cancer
cases. This BC treatment strategy allows for a better curerate and lower expenses and health resource utilization
(Legorreta et al. 1996; Lilliu et al. 2002; Lu et al. 2012;
Butler et al. 1995; Hillner 1996; Cady 1996).
An important strength of our model is the use of the
BC database, which reflects the standards of care in disease
management. The base case reflects the life expectancy of
Brazilian women, and QALYs were estimated from BC
patients. QALYs for a healthy state were calculated
based on the Brazilian population (Cruz 2010).
According to a recent government estimate, Brazil has
enough mammography devices to cover more than
70% of Brazilian women aged above 50 years (MS 2011).
Further, the country has deployed a program to improve
the quality of mammograms in the Brazilian public health
system (INCA 2009a). This adequate screening capacity
along with a quality program and cost-effective data
make the adoption of a national BC screening program
feasible and desirable in Brazil. In this study, we demon-
strate that a BC film-screening program every 2 years is
a cost-effective strategy.
Regarding digital mammography screening strategies,
annual screening by FFDM (Strategy E) was dominated
by Strategy F (age-targeted screening). As presented in
Figure 4, there was great variability in ICERs across the
country, mainly related to local BC incidence. This finding
suggests the importance of recognizing that for a large
heterogeneous country as Brazil regionalized health policy
must be considered by decision makers. For instance, in
the north, digital mammography screening should not be
recommended due to unfavorable cost-effectiveness. By
contrast, in the southeast and south of the country, where
BC incidences are higher, a digital age-targeted screening
program could be considered to be a good investment in
terms of value of money.
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machines in public institutions are obsolete (>8 years old),
the acquisition of replacement equipment is crucial. Thus,
health policies that incentivize the acquisition of digital
technology devices must be discussed for those regions with
high BC incidence (mainly the southeast, south, and some
areas of the northeast). In our view, this implementation
should be gradual in order to minimize the budget impact
from a short-term perspective, but it would allow the
public system to move towards more modern technol-
ogy. Although the main advantage of FFDM is seen for
younger women (<50 years), other potential benefits of
digitalization could be anticipated, such as the possibility
of teleradiology and the more reliable retrieval of exams
for future comparisons.
Our model estimates of incremental QALYs are similar
to those reported in previous studies in high-income coun-
tries (Tosteson et al. 2008; Szeto & Devlin 1996; Lindfors
& Rosenquist 1995), and we draw similar conclusions
about the advantages of BC screening in the younger popu-
lation. To the best of our knowledge, however, this is the
first cost-effectiveness analysis that focuses on age-targeted
digital mammography screening for women above 40 years
in low- and middle-income countries and that presents a
feasible strategy for an emerging country. We believe that
these results can be adapted to other emerging countries
with similar BC incidence rates and public healthcare
structures.
In conclusion, SFM every 2 years for all women starting
between the ages of 40 and 49 would be a cost-
effectiveness strategy to be incorporated by the Brazilian
public healthcare system. Taking into account regional
specificities, age-targeted digital screening is one option to
improve the outcomes of BC patients in an emerging
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